Hormonal
SGLT-2 inhibitors and GLP-1 receptor agonists significantly reduce major adverse cardiovascular events (MACE) and end-stage kidney disease (ESKD) in Type 2 Diabetes patients, with SGLT-2i showing specific superiority for kidney outcomes.
For Type 2 Diabetes patients with heart or kidney risks, prioritize SGLT-2 inhibitors or GLP-1 RAs. These drugs do more than lower blood sugar; they significantly reduce the risk of heart attacks, heart failure hospitalizations, and kidney failure. SGLT-2 inhibitors are particularly strong for protecting the kidneys.
Investigators found that both the SGLT-2i and GLP-1 RA medications were effective in reducing all-cause death, cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, and ESKD... SGLT-2i medications were shown to be superior to other medications in reducing end-stage kidney disease.
Why this rating
Based on 821 trials, 471,815 patients, using GRADE assessment.
Source
Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop
Antonio Ceriello et al. · Cardiovascular Diabetology · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →